“…Moreover, individual differences in amygdala function have been associated with clinical cardiovascular endpoints, cardiometabolic outcomes that are conducive to atherosclerotic CVD and even surrogate markers of pre-clinical atherosclerosis that are all presaged by autonomic, immune and neuroendocrine dysregulation. Elevated resting metabolic activity of the amygdala, for example, confers risk for cardiovascular events ( Tawakol et al., 2017 ), incident diabetes ( Osborne et al., 2019 ), the progression of visceral adiposity ( Ishai et al., 2019 ) and non-calcified coronary plaque ( Goyal et al., 2018 ). The latter findings build on earlier cross-sectional evidence that pre-clinical atherosclerosis in the carotid arteries associates with elevated metabolic activity in the medial temporal lobe ( Sojkova et al., 2010 ) and—more specifically—with amygdala reactivity to facial expressions of fear and anger ( Gianaros et al., 2008 ).…”